Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

June 11, 2019Open Access

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Synapse

Cite This Study

Husain et al. (Tue,) studied this question.

synapsesocial.com/papers/69d529b7af08f41283240717 https://doi.org/https://doi.org/10.1056/nejmoa1901118

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial2018 · 1,800 citations
2Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise2015 · 121 citations
3The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials2016 · 25 citations
4Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,025 citations
5Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial2019 · 3,054 citations